Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients
- 1 September 2002
- journal article
- research article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 40 (3) , 439-446
- https://doi.org/10.1053/ajkd.2002.34881
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators ProjectAmerican Journal of Kidney Diseases, 2001
- Intravenous versus subcutaneous dosing of Epoetin alfa in hemodialysis patientsAmerican Journal of Kidney Diseases, 1995
- Differences in Intravenous and Subcutaneous Application of Recombinant Human Erythropoietin: A Multicenter TrialArtificial Organs, 1994
- Recombinant ErythropoietinAsaio Journal, 1993
- Subcutaneous versus Intravenous Recombinant Human Erythropoietin Administration in Hemodialysis PatientsNephron, 1993
- Comparison of Subcutaneous and Intravenous Recombinant Human Erythropoietin for Anemia in Hemodialysis Patients with Significant Comorbid DiseaseAmerican Journal of Nephrology, 1992
- Once Weekly versus Twice Weekly Subcutaneous Administration of Recombinant Human Erythropoietin in Haemodialysis PatientsAmerican Journal of Nephrology, 1992
- Comparative Crossover Study of Intravenously and Subcutaneously Administered Recombinant Human Erythropoietin in Hemodialysis PatientsBlood Purification, 1992
- Recombinant Human Erythropoietin in Anemic Patients on Maintenance Hemodialysis: Comparison between Intravenous and Subcutaneous AdministrationNephron, 1991
- Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failureJournal of Internal Medicine, 1990